Italy retail sales fall 0.5% m/m in March
Shoppers walk along a shopping street ahead of Christmas in Rome, Italy, December 23, 2022. REUTERS/Guglielmo Mangiapane/File Photo Purchase Licensing Rights , opens new tab
May 7 (Reuters) - Italian retail sales fell 0.5% in March from the month before, data showed on Wednesday, following a 0.1% rise in February.
Sales fell 2.8% in unadjusted year-on-year terms in March, ISTAT said.
The Reuters Tariff Watch newsletter is your daily guide to the latest global trade and tariff news. Sign up here.
The data are expressed in value terms and are not adjusted for consumer prices, which increased 2.1% in March from the year earlier, based on Italy's EU-harmonised index(HICP).
ISTAT gave the following data:
Mar
Feb
Jan
Mth/Mth change*
-0.5
+0.1
-0.4
Yr/yr change**
-2.8
-1.4r
+0.9
Food sales (m/m)
-0.5
+0.2r
-0.4r
Non-food sales (m/m)
-0.3
0.0
-0.5
*seasonally adjusted
Advertisement · Scroll to continue
**unadjusted
r=revised
Reporting by Enrico Sciacovelli, editing by Valentina Consiglio
Our Standards: The Thomson Reuters Trust Principles. , opens new tab
Share X
Facebook
Linkedin
Email
Link
Purchase Licensing Rights
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
14 minutes ago
- Reuters
India's HDB Financial gets market regulator nod for IPO
MUMBAI/BENGALURU, June 3 (Reuters) - India's markets regulator, the Securities and Exchange Board of India (SEBI), has approved the initial public offering (IPO) of HDB Financial Services, marking the HDFC group's first public float in seven years. According to a document published on the SEBI website on Tuesday, the regulator issued observations on the public listing, allowing the company to proceed with its IPO, a source with direct knowledge of the matter said. SEBI and HDFC Bank ( opens new tab did not immediately respond to a Reuters request for comment. In October, HDB Financial filed for an IPO of up to 125 billion rupees ($1.5 billion). HDFC Bank, which holds a 94.3% stake in the lender, will sell shares worth up to 100 billion rupees, while fresh shares worth up to 25 billion rupees will be issued. HDB Financial's listing follows new norms introduced by the country's central bank in 2022 that require large non-banking financial companies to be listed on stock exchanges by September 2025. For the quarter ended March 31, HDB Financial Services posted a profit of 5.3 billion rupees, while its net revenue came in at 26.2 billion rupees. The company's total loan book was 1.07 trillion rupees as of March-end. ($1 = 85.6540 Indian rupees)
Reuters
16 minutes ago
- Reuters
Sanofi to buy US biopharma group Blueprint for up to $9.5 billion
PARIS, June 2 (Reuters) - France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European healthcare company so far this year, according to LSEG data. Blueprint (BPMC.O), opens new tab is a specialist in treatments for systemic mastocytosis, a rare blood disorder. Sign up here. The two companies said on Monday that Sanofi ( opens new tab would initially pay $129.00 per share in cash, or around $9.1 billion. Blueprint shares jumped 27% to $128.74 in premarket trade. Sanofi stock was down about 1%. Sanofi has ramped up research and development spending in recent years, prompting the company to abandon its long-term profit margin targets two years ago, as it seeks to build on the success of its blockbuster drug Dupixent for eczema and other conditions. However, it suffered a setback last week after an experimental drug for patients with a lung condition commonly called "smoker's lung" failed a late-stage trial. The Blueprint acquisition "represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company," said Sanofi CEO Paul Hudson. The deal would add to Sanofi's portfolio the rare immunology disease drug Ayvakit, also known as Ayvakyt, approved in the U.S. and the EU, and a promising advanced and early-stage immunology pipeline. Ayvakit is the only approved medicine for advanced and indolent systemic mastocytosis, a rare blood disorder that occurs when the body makes abnormal mast cells - a type of white blood cell. It triggers a continuous allergic response. The acquisition would also bring elenestinib, a next-generation medicine for systemic mastocytosis, as well as BLU-808, a highly selective and potent oral wild-type KIT inhibitor that has the potential to treat a broad range of diseases in immunology. The deal makes "strategic and financial sense", said JP Morgan analysts in a note, noting that Blueprint expects Ayvakit to reach annual sales of around $2 billion by fiscal year 2030. "We see the transaction as a good fit for Sanofi at a sensible valuation, which investors should see as a positive with time," they added. It is the latest in a series of deals by Sanofi. Last month, it announced the $470 million purchase of Vigil Neuroscience (VIGL.O), opens new tab and in January 2024 it struck a $2.2 billion deal for U.S biotech firm Inhibrx. Hudson said the deal complemented Sanofi's recent acquisitions of other early-stage medicines and added that it still retained a sizable capacity for further deals. The company has said it plans to invest at least $20 billion in the United States through 2030 to boost manufacturing and research, joining other drugmakers in responding to President Donald Trump's drive to boost local manufacturing. Besides $129.00 per share in cash, Blueprint shareholders would also receive one non-tradeable contingent value right (CVR) per share, which would entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The total equity value of the transaction, including potential CVR payments, is $9.5 billion on a fully diluted basis. It is expected to close in the third quarter, pending regulatory and shareholder approvals.
Reuters
24 minutes ago
- Reuters
Energy storage system based on EV batteries launched at Rome's airport
ROME, June 3 (Reuters) - Italy's largest energy storage system based on used batteries for electric vehicles was inaugurated on Tuesday at Rome's Fiumicino airport to help it reduce carbon emissions. The system called 'Pioneer' has been developed by Italian utility Enel ( opens new tab and airport operator ADR and is one of the largest of its kind in Europe, the two companies said in a statement. It will be used to store energy produced by a solar farm Enel opened in Fiumicino in January. As Italy rolls out an increasing number of renewable energy projects, it needs storage systems to make energy available when the sun or wind are not powering its green energy plants. Using material provided by automakers Nissan (7201.T), opens new tab, Mercedes ( opens new tab and Stellantis ( opens new tab, 'Pioneer' will turn 762 battery packs and modules that can no longer be used for vehicles into a 10 megawatt-hour battery energy storage system, Enel and ADR said. That is roughly equivalent to the electricity that would be needed to power 3,000 U.S. homes for a day. According to Enel and ADR, the system should reduce CO2 emissions by around 16,000 tons over ten years.
